Follow The Filings

IMCR Immunocore

Immunocore earnings company data as of 4:47 AM ET 10/24

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by IMCR's executives, directors and 10% owners in the last 12 months, from their Form 4s

All IMCR insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $5M sold by 1 insider under 10b5-1 plans
  1. David M Berman Head of R&D
    Planned sale
    $1.3M 31,913 shares at $40.26 100% of stake
    Traded Dec 4–5 Filed Dec 8, 2025
    ↗
  2. David M Berman Head of R&D
    Planned sale
    $3M 74,925 shares at $40.12 100% of stake
    Traded Nov 26–28 Filed Dec 1, 2025
    ↗
  3. David M Berman Head of R&D
    Planned sale
    $725K 18,120 shares at $40.03 100% of stake
    Traded Nov 24–25 Filed Nov 26, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 10 option exercises and 4 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEF 14A Filing Doc
SCHEDULE 13G/A — Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02 Filing Doc
8-K 2.02,7.01,8.01,9.01 Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.